Dermatitis®
Reasons for Upadacitinib Discontinuation and Risk of Recurrence in the Treatment of Atopic Dermatitis
Background: Treatment discontinuation is common with Janus kinase inhibitors, such as upadacitinib, in moderate-to-severe atopic dermatitis (AD), and this often results in disease relapse and an increased patient burden. Objective: To explore reasons for discontinuation, risk factors, and willingness to reuse upadacitinib. Methods: This retrospective study enrolled 104 patients with AD (50 in the discontinuation, 54 in the non-discontinuation) from Xiangya Third Hospital (Feb–Mar 2026). Data on DLQI, pruritus NRS, …